Beijing FivePlus Molecular Medicine Institute

Beijing FivePlus Molecular Medicine Institute is a specialized biotechnology company and CDMO focused on the development and manufacturing of gene therapy products. Established in 2005, the company provides end-to-end services for viral vectors, including AAV, adenovirus, and lentivirus, supporting clients from early-stage research to clinical production. FivePlus utilizes its proprietary vYeast platform to optimize AAV production and maintains an internal pipeline of gene therapies for rare genetic disorders. The institute is a key player in the Chinese gene therapy ecosystem, operating high-standard GMP facilities in Beijing to support both internal programs and external partnerships.